Modern antiretroviral regimens in pregnant women: virologic outcomes and durability
- 6 June 2023
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 38 (1) , 21-29
Abstract
Objectives: Data are lacking on the virologic efficacy and durability of modern antiretroviral treatment (ART) regimens during pregnancy. We compared virologic outcomes at delivery among women receiving dolutegravir versus other ART and the rate of change of the initial pregnancy regimen. Design: Single-site retrospective cohort between 2009 and 2019. Methods: We used univariable and multivariable generalized estimating equations to model the relationship between the maternal ART anchor and the proportion of women with a detectable viral load (greater than or equal to 20 HIV RNA copies/mL of plasma) closest to delivery (suboptimal virologic control) and with a detectable viral load at any time in the third trimester. We also compared changes in ART during pregnancy. Results: We evaluated 230 pregnancies in 173 mothers. Rates of optimal virologic control at delivery did not significantly differ in mothers who received dolutegravir (93.1%), rilpivirine (92.1%), boosted darunavir (82.6%), or efavirenz (76.9%) but were significantly lower among mothers receiving atazanavir (49.0%) or lopinavir (40.9%). The odds of having a detectable viral load at any time in the third trimester was also higher for atazanavir and lopinavir. Raltegravir, elvitegravir, or bictegravir were used in less than 10 mothers at delivery, which precluded statistical analyses. The frequency of change in ART was significantly higher in mothers who initially received elvitegravir (68%) or efavirenz (47%) than dolutegravir (18%). Conclusion: Dolutegravir-containing, rilpivirine-containing, and boosted darunavir-containing regimens conferred excellent virologic control in pregnancy. Atazanavir and lopinavir, elvitegravir, and efavirenz were associated with either high rates of virologic failure or regimen change during pregnancy.Keywords
This publication has 20 references indexed in Scilit:
- Cobicistat-containing antiretroviral regimens are not recommended during pregnancyAIDS, 2019
- Barrier to Resistance of Dolutegravir in Two-Drug CombinationsAntimicrobial Agents and Chemotherapy, 2019
- Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIVAIDS, 2018
- Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant womenHIV Research & Clinical Practice, 2018
- Integrase inhibitors in late pregnancy and rapid HIV viral load reductionAmerican Journal of Obstetrics and Gynecology, 2016
- Raltegravir Pharmacokinetics During PregnancyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Efavirenz‐ but not nevirapine‐based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub‐dermal contraceptive implantJournal of the International AIDS Society, 2014
- Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000–2011AIDS, 2014
- Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE StudiesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2012
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009